Valo Health’s Rho kinase (ROCK) 1 and 2 inhibitor has failed to reduce the severity of diabetic retinopathy in a phase 2 trial, leading the Flagship-founded biotech to drop the candidate.
On the last day of 2024, Lexington’s Valo Health Inc. also shared that its Phase 2 trial of OPL-0401 in patients with diabetic retinopathy did not meet its primary or secondary end ...
Novo Nordisk A/S and Valo Health, Inc. today announced they have entered into an expanded agreement to discover and develop ...
Novo Nordisk’s collaboration with artificial intelligence startup Valo Health has focused on developing new drugs for cardiovascular disease. The pharmaceutical giant likes what it’s seen so ...
Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and ...
(RTTNews) - Novo Nordisk A/S (NVO), Wednesday announced an expansion of its collaboration with Valo Health to discover and develop novel treatments for obesity, type-2 diabetes, and cardiovascular ...
The companies originally partnered in September 2023 in an agreement that allowed for the development of up to 11 drug programmes, primarily focused on cardiovascular disease, through which Valo ...
Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and cardiometabolic diseases, leveraging AI and extensive human datasets.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback